Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORWARD II: Mirvetuximab Soravtansine Combinations in Ovarian Cancer
NCT02606305Phase 2Completed
- Sponsor
- ImmunoGen
- Start
- Mar 2016
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of mirvetuximab soravtansine in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (5 arms), sponsored by ImmunoGen. Primary endpoints: Treatment-Emergent Adverse Events and Objective Response Rate. Started Mar 2016; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02606305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606305.